CureVac N.V. Stock

Equities

CVAC

NL0015436031

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-13 pm EDT 5-day change 1st Jan Change
4 USD -3.61% Intraday chart for CureVac N.V. -19.84% -4.99%
Sales 2024 * 56.61M 60.76M Sales 2025 * 86.44M 92.78M Capitalization 834M 895M
Net income 2024 * -211M -226M Net income 2025 * -130M -140M EV / Sales 2024 * 13.2 x
Net cash position 2024 * 86.36M 92.69M Net cash position 2025 * 184M 198M EV / Sales 2025 * 7.51 x
P/E ratio 2024 *
-3.87 x
P/E ratio 2025 *
-6.93 x
Employees 1,086
Yield 2024 *
-
Yield 2025 *
-
Free-Float 54.73%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.61%
1 week-19.84%
Current month+2.83%
1 month+34.68%
3 months+18.69%
6 months-24.39%
Current year-4.99%
More quotes
1 week
3.93
Extreme 3.925
4.60
1 month
3.10
Extreme 3.1
5.28
Current year
2.22
Extreme 2.215
5.28
1 year
2.22
Extreme 2.215
12.36
3 years
2.22
Extreme 2.215
101.00
5 years
2.22
Extreme 2.215
151.80
10 years
2.22
Extreme 2.215
151.80
More quotes
Managers TitleAgeSince
Chief Executive Officer 54 23-03-27
Director of Finance/CFO 50 16-10-31
Chief Operating Officer 59 21-06-30
Members of the board TitleAgeSince
Director/Board Member 58 19-05-31
Director/Board Member 69 23-06-18
Director/Board Member 67 22-06-21
More insiders
Date Price Change Volume
24-06-13 4 -3.61% 806,615
24-06-12 4.15 -2.35% 730,337
24-06-11 4.25 -7.41% 1,384,811
24-06-10 4.59 +2.23% 992,798
24-06-07 4.49 -10.02% 1,734,608

Delayed Quote Nasdaq, June 13, 2024 at 04:00 pm EDT

More quotes
CureVac AG is a clinical-stage biopharmaceutical company, The Company strives to create transformative medicines to protect and improve people’s lives. Fueled by proprietary RNA technology platform combined with two decades of science and manufacturing, The Company is dedicated to creating novel treatments that enable the body to make its own prophylactic and therapeutic drugs.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
3.716 EUR
Average target price
8.728 EUR
Spread / Average Target
+134.87%
Consensus